Table 1.
Clinical and biochemical characteristics of the study population.
| Parameter | Mean ± Standard Deviation Rate (%) | Median (25°–75° Percentile) |
|---|---|---|
| Age (years) | 43.7 ± 9.6 | 42 (38–49) |
| Gender (M%) | 24% | - |
| BMI (kg/m2) | 43.6 ± 5.6 | 42.2 (40–47.4) |
| Waist circumference (cm) | 128 ± 11.4 | 126 (126–135.5) |
| SBP (mmHg) | 128.3 ± 16.1 | 130 (120–136) |
| DBP (mmHg) | 84.8 ± 18.2 | 80 (80–85) |
| Total Cholesterol (mg/dL) | 196 ± 32.4 | 194.5 (176.2–207) |
| HDL (mg/dL) | 48.2 ± 10.4 | 48 (39–55) |
| LDL (mg/dL) | 120.3 ± 29.7 | 120 (120–137) |
| Triglycerides (mg/dL) | 129.5 ± 44.9 | 127 (127–160) |
| FBG (mg/dL) | 104 ± 22.4 | 95 (90–120) |
| HbA1c (%—mmol/mol) | 5.9 ± 1 | 5.3 (5.1–5.8) |
| FBI (µU/L) | 16.8 ± 15.1 | 11.5 (9.7–16.6) |
| HOMA-IR | 4.5 ± 4.7 | 2.8 (2.2–4) |
| HOMA-β% | 164 ± 120 | 133.5 (67.8–212) |
| Pro-NT (pmol/L) | 178.6 ± 85 | 159.4 (118–216.9) |
| T2D (%) | 15% | - |
| MS (%) | 80% | - |
| NAFLD (%) | 50% | - |
| NASH (%) | 25% | - |
| Therapy with antidiabetic agents | 15% | - |
| Therapy with statins | 92% | - |
| Therapy with anti-hypertensive medications | 73% | - |